JANX Janux Therapeutics Inc

$24.30

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Janux Therapeutics Inc. (JANX) is poised for its upcoming earnings announcement on August 12, 2025, with a market cap of approximately $1.39 billion, reflecting investor confidence in its innovative biopharmaceutical pursuits. Despite the absence of recent news, the company's strategic focus on developing next-generation immunotherapies continues to capture market interest. Analysts are anticipating an EPS of $0.00, aligning with the whisper number, while revenue is projected at $250,000. This revenue estimate, though modest, underscores Janux's early-stage development phase, where the emphasis remains on research and development rather than immediate profitability. Investors will be keenly observing any updates on pipeline progress or strategic partnerships that could signal future growth potential. As Janux navigates this critical phase, meeting or exceeding these expectations could reinforce market sentiment and support its valuation trajectory.

Updated On 8/22/2025

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.

Website: https://www.januxrx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1817713
Address
11099 TORREY PINES PARK ROAD, SAN DIEGO, CA, US
Valuation
Market Cap
$1.75B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.72
Performance
EPS
$-1.28
Dividend Yield
—
Profit Margin
0.00%
ROE
-10.10%
Technicals
50D MA
$31.42
200D MA
$43.72
52W High
$71.71
52W Low
$22.52
Fundamentals
Shares Outstanding
59M
Target Price
$85.33
Beta
3.27

JANX EPS Estimates vs Actual

● Estimated
● Actual

JANX News & Sentiment

Aug 07, 2025 • Motley Fool NEUTRAL
Janux ( JANX ) R&D Soars Revenue Misses
Janux Therapeutics ( NASDAQ:JANX ) , a clinical-stage biotechnology company focused on developing next-generation immunotherapies, reported second quarter results on August 7, 2025. The main headline: the company posted a net loss as it continued to invest heavily in its pipeline, with GAAP ...
Jul 11, 2025 • Benzinga SOMEWHAT-BULLISH
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Harrow ( NASDAQ:HROW ) , Janux Therapeutics ( NASDAQ:JANX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ladenburg Thalmann analyst Aydin Huseynov initiated coverage on KALA BIO, Inc.
Dec 04, 2024 • Motley Fool SOMEWHAT-BULLISH
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics ( NASDAQ: JANX ) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P ...
Dec 04, 2024 • Zacks Commentary NEUTRAL
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
Dec 03, 2024 • Benzinga NEUTRAL
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Janux Therapeutics ( NASDAQ:JANX )
JANX007 showed strong efficacy in metastatic castration-resistant prostate cancer, with 100% achieving PSA50 declines. The therapy demonstrated durability irrespective of prior treatments. Benzinga shares with you top insiders news On Monday, Janux Therapeutics, Inc.
Dec 03, 2024 • Benzinga SOMEWHAT-BULLISH
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Credo Technology Group ( NASDAQ:CRDO ) , Aptorum Gr ( NASDAQ:APM )
Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results issued guidance that was above estimates. Credo Technology Group shares jumped 40.2% to $67.00 in the pre-market trading ...
Sentiment Snapshot

Average Sentiment Score:

0.192
50 articles with scored sentiment

Overall Sentiment:

Bullish

JANX Reported Earnings

Feb 28, 2025
Dec 31, 2024 (Pre market)
0.09 Surprise
  • Reported EPS: $-0.36
  • Estimate: $-0.45
  • Whisper: —
  • Surprise %: 20.6%
Nov 07, 2024
Sep 30, 2024 (Pre market)
-0.15 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: -43.0%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.2 Surprise
  • Reported EPS: $-0.11
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: 64.5%
May 07, 2024
Mar 31, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.33
  • Whisper: —
  • Surprise %: 9.1%
Mar 08, 2024
Dec 31, 2023 (Post market)
0.16 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: 39.0%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.22 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.47
  • Whisper: —
  • Surprise %: 46.8%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.1 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: 19.2%
May 09, 2023
Mar 31, 2023 (Post market)
0.07 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 14.3%
Mar 10, 2023
Dec 31, 2022 (Post market)
0.1 Surprise
  • Reported EPS: $-0.39
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 20.4%

Financials